Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna MRNA shares are set to join the Nasdaq-100 Index on Oct. 9, marking another milestone for the biotech after its sharp ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock.

Moderna Therapeutics is well acquainted with managing evolution, so perhaps it's no surprise that the firm's vice president ...

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Australia’s leading science agency has teamed up with a pharmaceutical giant to help prevent future biosecurity threats. A five-year partnership has been signed between the CSIRO and Moderna for a ...

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.